(MedPage Today) — The FDA added a boxed warning to delandistrogene moxeparvovec (Elevidys) gene therapy for Duchenne muscular dystrophy and changed the indication of the drug after reports of fatal liver injury emerged, the agency announced Friday…
Source link : https://www.medpagetoday.com/neurology/generalneurology/118544
Author :
Publish date : 2025-11-14 22:35:00
Copyright for syndicated content belongs to the linked Source.
